The Efficacy of N-acetylcysteine as an adjunctive treatment in unipolar depression

N-乙酰半胱氨酸辅助治疗单相抑郁症的疗效

• 批准号: nhmrc : 628395
• 负责人: A/Pr Seetal Dodd
• 金额: $ 29.59万
• 依托单位: Deakin University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/efficacy-n-acetylcysteine-unipolar-depression/100472
• 关键词: Efficacy; acetylcysteine; adjunctive; treatment; unipolar

This is evidence that the brain's antioxidant defences, particularly glutathione, are altered in depression. N-acetylcysteine (NAC), a glutathione precursor, increases antioxidant defences and has antidepressant properties in bipolar disorder. The aim of this study is to see if treatment with NAC will precent relapse and improve the symptoms of depression including functioning and quality of life. Participants will be randomly given either NAC or placebo, in addition to standard thereapy.

这证明大脑的抗氧化防御，特别是谷胱甘肽，在抑郁症中发生了改变。N-乙酰半胱氨酸（NAC），谷胱甘肽前体，增加抗氧化防御，并在双相情感障碍中具有抗抑郁特性。本研究的目的是观察NAC治疗是否能预防复发并改善抑郁症的症状，包括功能和生活质量。参与者将被随机给予NAC或安慰剂，以及标准治疗。